Bob Nelsen (Lyell)
Updated: As bear market continues to beat down biotech, ARCH closes a $3B early-stage fund
One of the biggest names in biotech investing has a whole lot of new money to spend.
ARCH Venture Partners closed its 12th venture fund …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
